XPO1

Overview

XPO1 encodes nuclear export receptor CRM1 and is recurrently mutated in classic Hodgkin lymphoma.

Alterations observed in the corpus

  • XPO1 was mutated in 8% of classic Hodgkin lymphoma cases PMID:36723991.
  • XPO1 was identified as a high-risk clonal hematopoiesis (CH) genotype conferring particularly high risk of subsequent hematologic malignancy in 42,714 MSK patients with nonhematologic cancer PMID:38147626.
  • Recurrently mutated in CLL WES of 160 tumors (Broad Institute cohort); XPO1 encodes exportin-1, a nuclear export protein, and the hotspot E571K mutation is highly recurrent in CLL PMID:23415222
  • XPO1 harbors a recurrent D624G missense mutation in ESCC with protein and mRNA overexpression; therapeutic target via KPT-330 (selinexor) PMID:24686850
  • Previously reported driver candidate not confirmed as a PFS hit in the CLL8 trial in a 538-patient WES study PMID:26466571
  • GCB-selective CRISPR essential dependency in DLBCL; knockout of XPO1 was selectively lethal in GCB DLBCL cell lines but not ABC DLBCL, nominating selinexor as a candidate GCB-directed therapy PMID:28985567.

Cancer types (linked)

  • CHL — 8% mutated PMID:36723991.
  • DLBCLNOS — GCB-selective CRISPR essential dependency; XPO1 knockout was selectively lethal in GCB DLBCL cell lines across a genome-wide CRISPR screen PMID:28985567.

Co-occurrence and mutual exclusivity

  • Not reported in the corpus.

Therapeutic relevance

  • Selinexor (KPT-330) targets XPO1 nuclear export function; nominated as a GCB-directed therapy based on GCB-selective CRISPR essentiality in DLBCL PMID:28985567. Also reported as a therapeutic target in ESCC (D624G missense, mRNA overexpression) PMID:24686850.

Open questions

  • None specific to XPO1 in the corpus.

Sources

This page was processed by entity-page-writer on 2026-05-15.